Management Strategies and Outcomes for Type 1 Gastric Neuroendocrine Tumors Measuring More Than 1 cm
Authors:
- Elisabetta Dell’UNtoEDElisabetta Dell’UNto
- Rajaventhan SrirajaskanthanRSRajaventhan Srirajaskanthan
- Christos ToumpanakisChristos Toumpanakis
- Louis de MestierLouis de Mestier
- Dermot O'TOoleDODermot O'TOole
- Davide CampanaDCDavide Campana
- D. Mark PritchardDPD. Mark Pritchard
- Gianluca EspositoGEGianluca Esposito
- Maria RinzivilloMRMaria Rinzivillo
- Dalvinder MandairDMDalvinder Mandair
- Aman SainiASAman Saini
Open Access
- 17 August 2026
- journal article
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (10) , e01083
Abstract
INTRODUCTION: Type 1 gastric neuroendocrine tumors (T1g-NETs) are well-differentiated lesions with excellent survival but frequent recurrence. Tumor size is the main prognostic factor, yet optimal management for tumors >1 cm remains uncertain. This study aimed to evaluate treatment strategies and outcomes in patients with T1g-NETs>1 cm. METHODS: We conducted a retrospective multicenter study including 106 adults with T1g-NETs >1 cm. Clinicopathologic and management data were collected. The primary outcome event was a composite unfavorable outcome, defined as recurrence or progression, used to analyze progression-free survival (PFS) as the main time-to-event outcome. Analyses included multinomial logistic regression, Cox models, and Kaplan–Meier curves ( P < 0.05). RESULTS: Among 106 patients (58.5% female; median age 59), median tumor size was 15 mm. Most tumors were Grade 1 (61.4%) or Grade 2 (37.7%), with median Ki-67 of 2%. Endoscopic resection was performed in 76 patients (71.7%), surgery in 33 (31.1%, including 13 initially treated endoscopically), and 10 (9.4%) were surveilled. Over a median 61-month follow-up, 24 patients (22.6%) recurred, 8 (7.5%) progressed; only 2 deaths (1.9%) were tumor-related. Larger tumors were associated with unfavorable outcome ( P = 0.005), with lesions ≥24 mm predicting shorter PFS (hazard ratio 3.93; P < 0.001). Endoscopic submucosal dissection and modified-endoscopic mucosal resection were associated with a significantly longer PFS ( P = 0.004). R0 resection showed a borderline protective effect. Five-year overall survival approached 95%. DISCUSSION: T1g-NETs > 1 cm frequently recur and may exhibit aggressive potential, particularly when lesions are larger. When endoscopic resection is feasible, endoscopic submucosal dissection or modified-endoscopic mucosal resection should be preferred to optimize outcomes.Keywords
Funding Information
- Ministero dell'Università e della Ricerca (Bando 2022 PNRR (Prot. P2022PS7AC))
This publication has 19 references indexed in Scilit:
- Outcomes of device assisted endoscopic full thickness resection in gastroduodenal submucosal lesions: A large, multicentre study (with videos)Digestive and Liver Disease, 2025
- The indolent nature of type 1 gastric neuroendocrine tumors under 1 cmDigestive and Liver Disease, 2025
- World Medical Association Declaration of HelsinkiJAMA, 2025
- Gastric neuroendocrine neoplasmsNature Reviews Disease Primers, 2024
- Management of type-I gastric neuroendocrine neoplasms: A 10-years prospective single centre studyDigestive and Liver Disease, 2022
- Overview of the 2022 WHO Classification of Neuroendocrine NeoplasmsEndocrine Pathology, 2022
- Clinical Outcomes of Endoscopic Treatment for Type 1 Gastric Neuroendocrine TumorJournal of Gastrointestinal Surgery, 2021
- Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective studyDigestive and Liver Disease, 2019
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- A simulation study of the number of events per variable in logistic regression analysisJournal of Clinical Epidemiology, 1996